B淋巴细胞刺激因子/增殖诱导配体（BLyS/BAFF）配体与受体家族：自身免疫治疗及理解中的关键靶点
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity.
作者信息
Cancro M P
机构信息
Department of Pathology, 284 John Morgan Building, University of Pennsylvania School of Medicine, 36th and Hamilton Walk, Philadelphia, PA 19104-6082, USA.
出版信息
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii34-6. doi: 10.1136/ard.2006.058412.
Abstract
The B lymphocyte stimulator (BLyS; also termed BAFF) family of ligands and receptors plays a central role in B lymphocyte development, selection, and homoeostasis. Members of this family can independently influence different B cell subsets, because the interactions between the two ligands and three receptors vary, and the receptors themselves are differentially expressed among developing, naive, and antigen experienced B cell subsets. These properties prompt careful assessment of how ablative therapies may influence the behaviour of upstream or downstream B lineage populations, as well as how the implementation and expectations of therapeutics targeting BLyS family members must be guided by knowledge of the B cell subsets contributing to pathogenesis.
摘要
B淋巴细胞刺激因子（BLyS；也称为BAFF）配体和受体家族在B淋巴细胞的发育、选择和稳态中起着核心作用。该家族成员可独立影响不同的B细胞亚群，因为两种配体与三种受体之间的相互作用各不相同，且这些受体在发育中的、未活化的以及经历过抗原刺激的B细胞亚群中表达各异。这些特性促使我们仔细评估消融疗法如何影响上游或下游B细胞谱系群体的行为，以及针对BLyS家族成员的治疗方法的实施和预期如何必须以对参与发病机制的B细胞亚群的了解为指导。
相似文献
1
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity.B淋巴细胞刺激因子/增殖诱导配体（BLyS/BAFF）配体与受体家族：自身免疫治疗及理解中的关键靶点
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii34-6. doi: 10.1136/ard.2006.058412.
2
Manipulating B cell homeostasis: a key component in the advancement of targeted strategies.调控B细胞稳态：靶向治疗策略进展中的关键要素。
Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):153-64. doi: 10.1007/s00005-008-0017-2. Epub 2008 May 30.
3
The BLyS family: toward a molecular understanding of B cell homeostasis.B淋巴细胞刺激因子家族：对B细胞稳态的分子理解
Cell Biochem Biophys. 2009;53(1):1-16. doi: 10.1007/s12013-008-9036-1. Epub 2008 Nov 26.
4
B-cell homeostasis requires complementary CD22 and BLyS/BR3 survival signals.B 细胞的稳态需要互补的 CD22 和 BLyS/BR3 生存信号。
Int Immunol. 2010 Aug;22(8):681-91. doi: 10.1093/intimm/dxq055. Epub 2010 May 31.
5
The late news on baff in autoimmune diseases.自身免疫性疾病中 baff 的最新消息。
Autoimmun Rev. 2010 Oct;9(12):804-6. doi: 10.1016/j.autrev.2010.06.011. Epub 2010 Jul 23.
6
BAFF inhibition: a new class of drugs for the treatment of autoimmunity.BAFF 抑制：一类用于治疗自身免疫的新药。
Exp Cell Res. 2011 May 15;317(9):1270-7. doi: 10.1016/j.yexcr.2011.02.005. Epub 2011 Feb 17.
7
The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus.B 淋巴细胞刺激因子在 B 细胞生物学中的作用：对狼疮治疗的启示。
Lupus. 2013 Apr;22(4):350-60. doi: 10.1177/0961203312469453.
8
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.替利昔单抗作为 BLyS/APRIL 的双重抑制剂用于自身免疫性疾病。
Immunopharmacol Immunotoxicol. 2021 Dec;43(6):666-673. doi: 10.1080/08923973.2021.1973493. Epub 2021 Sep 14.
9
Mechanism of BLyS action in B cell immunity.B淋巴细胞刺激因子（BLyS）在B细胞免疫中的作用机制。
Cytokine Growth Factor Rev. 2002 Feb;13(1):19-25. doi: 10.1016/s1359-6101(01)00025-9.
10
The role of BAFF and APRIL in rheumatoid arthritis.BAFF 和 APRIL 在类风湿关节炎中的作用。
J Cell Physiol. 2019 Aug;234(10):17050-17063. doi: 10.1002/jcp.28445. Epub 2019 Apr 2.
引用本文的文献
1
Therapeutic Potential of Lipid Nanoparticle-Encapsulated CD19-Targeting mRNAs in Lupus and Rheumatoid Arthritis.脂质纳米颗粒包裹的靶向CD19的mRNA在狼疮和类风湿性关节炎中的治疗潜力
Adv Sci (Weinh). 2025 Jun;12(21):e2501628. doi: 10.1002/advs.202501628. Epub 2025 Apr 7.
2
Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.临床实践中系统性红斑狼疮不断发展的治疗策略：一项叙述性综述
Cureus. 2024 Dec 3;16(12):e75062. doi: 10.7759/cureus.75062. eCollection 2024 Dec.
3
Immunotherapy for Pemphigus: Present and Future.天疱疮的免疫疗法：现状与未来
Front Med (Lausanne). 2022 Jun 15;9:901239. doi: 10.3389/fmed.2022.901239. eCollection 2022.
4
Altered Germinal-Center Metabolism in B Cells in Autoimmunity.自身免疫中B细胞生发中心代谢的改变。
Metabolites. 2022 Jan 5;12(1):40. doi: 10.3390/metabo12010040.
5
Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.确定免疫抑制剂的安全阈值：应用原发性抗体缺陷的见解，通过对临床前和早期临床数据的数学建模来减轻继发性抗体缺陷的不良事件。
Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):601-611. doi: 10.1007/s13318-021-00706-z. Epub 2021 Jul 30.
6
Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.先天免疫与生物疗法治疗干燥综合征。
Int J Mol Sci. 2020 Dec 1;21(23):9172. doi: 10.3390/ijms21239172.
7
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.噬菌体展示技术衍生的单克隆抗体：从实验室到临床。
Front Immunol. 2020 Aug 28;11:1986. doi: 10.3389/fimmu.2020.01986. eCollection 2020.
8
Regulatory and Memory B Lymphocytes in Children With Newly Diagnosed Immune Thrombocytopenia.新诊断免疫性血小板减少症患儿的调节性B淋巴细胞和记忆性B淋巴细胞
J Hematol. 2017 Oct;6(4):81-86. doi: 10.14740/jh336w. Epub 2017 Sep 20.
9
B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.利妥昔单抗治疗后复发的类风湿性关节炎患者的B细胞表型：B细胞亚群上B细胞活化因子结合受体的表达
Clin Exp Immunol. 2017 Dec;190(3):372-383. doi: 10.1111/cei.13024. Epub 2017 Sep 25.
10
Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.利妥昔单抗对血栓性血小板减少性紫癜患者B细胞表型及血清B细胞活化因子水平的影响
Clin Exp Immunol. 2015 Mar;179(3):414-25. doi: 10.1111/cei.12472.
本文引用的文献
1
Space, selection, and surveillance: setting boundaries with BLyS.空间、选择与监测：与B淋巴细胞刺激因子划定界限
J Immunol. 2006 Jun 1;176(11):6405-10. doi: 10.4049/jimmunol.176.11.6405.
2
The role of APRIL and BAFF in lymphocyte activation.增殖诱导配体（APRIL）和B细胞活化因子（BAFF）在淋巴细胞激活中的作用。
Curr Opin Immunol. 2005 Jun;17(3):282-9. doi: 10.1016/j.coi.2005.04.005.
3
Homeostatic niche specification among naïve and activated B cells: a growing role for the BLyS family of receptors and ligands.初始B细胞和活化B细胞之间的稳态微环境特化：BLyS受体和配体家族的作用日益凸显。
Semin Immunol. 2005 Jun;17(3):193-9. doi: 10.1016/j.smim.2005.02.001.
4
The role of BAFF in immune function and implications for autoimmunity.BAFF在免疫功能中的作用及其对自身免疫的影响。
Immunol Rev. 2005 Apr;204:43-54. doi: 10.1111/j.0105-2896.2005.00219.x.
5
Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors.人类B淋巴细胞恶性肿瘤：对B淋巴细胞刺激因子（BLyS）和增殖诱导配体（APRIL）及其受体的利用
Curr Dir Autoimmun. 2005;8:266-88. doi: 10.1159/000082107.
6
The BAFF/APRIL system: an important player in systemic rheumatic diseases.BAFF/APRIL系统：系统性风湿性疾病中的重要角色。
Curr Dir Autoimmun. 2005;8:243-65. doi: 10.1159/000082106.
7
The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation.B淋巴细胞刺激因子（BLyS）配体与受体家族：特异性小生境稳态调节的原型
Immunol Rev. 2004 Dec;202:237-49. doi: 10.1111/j.0105-2896.2004.00212.x.
8
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding.增殖诱导配体（APRIL）-受体复合物的结构：与B细胞成熟抗原（BCMA）一样，跨膜激活剂和钙调亲环素配体相互作用分子（TACI）仅利用单个富含半胱氨酸的结构域进行高亲和力配体结合。
J Biol Chem. 2005 Feb 25;280(8):7218-27. doi: 10.1074/jbc.M411714200. Epub 2004 Nov 12.
9
A therapeutic role for BLyS antagonists.
Lupus. 2004;13(5):317-22. doi: 10.1191/0961203304lu1019oa.
10
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.过量的B淋巴细胞刺激因子可使自身反应性B细胞免于外周清除，并使其进入被禁止的滤泡和边缘区微环境。
Immunity. 2004 Jun;20(6):785-98. doi: 10.1016/j.immuni.2004.05.010.
Zotero 插件